Can You Get Measles Twice in Your Life?

After a natural measles infection, the immunity you develop is essentially lifelong, making a true second bout of measles extraordinarily rare. The virus triggers such a powerful immune response that survivors retain protective antibodies and immune memory for decades. The more practically relevant question for most people today is whether measles can strike someone who was vaccinated, and the answer there is more nuanced: vaccine-induced immunity, while highly effective, can fade over time, and a small percentage of vaccinated people do end up getting measles during outbreaks.

Why Natural Infection Creates Such Durable Immunity

Measles is one of the most immunogenic viruses known to science. When wild-type measles virus infects a person, it replicates extensively in the lymphoid tissue before the immune system stamps it out. That deep, widespread engagement with the immune system is what makes the resulting protection so robust. Research in macaques has confirmed that wild-type measles infection triggers lifelong protective immunity in survivors, driven by the virus’s aggressive replication in immune tissues throughout the body.¹ The immune system mounts both an antibody response and a cellular response involving specialized T cells, and both arms of that defense persist long after the infection clears.

An Italian retrospective study comparing people who had survived natural measles to those who received two doses of the MMR vaccine found that immunity after the disease appears to be lifelong, while the vaccine-induced response tends to decline within roughly ten to fifteen years.² That gap does not mean the vaccine is weak. It means wild infection is an extraordinarily intense immunological event, one that leaves deeper footprints in the body’s immune memory than a vaccine designed to be safe and well-tolerated.

How Vaccine-Induced Immunity Fades

Measles vaccines use a live but weakened form of the virus. This weakened virus replicates just enough to train your immune system without causing disease, but the replication is far more limited than what happens in a natural infection. The result is a robust but not quite permanent immune response. Over the years, antibody levels can slowly drift downward.

A Mexican study measured measles antibody levels across different birth cohorts and found a striking pattern. People born before 1970, in the era before widespread vaccination, had the highest antibody levels by far, because most of them had survived wild measles as children. Younger cohorts who grew up in the vaccine era had significantly lower antibody concentrations, and the trend was consistent: the more recent the birth cohort, the lower the average antibody level.³ Interestingly, the number of vaccine doses a person had received did not make a statistically significant difference in antibody levels. Whether someone reported one dose, two, or even three, their antibody concentrations were similar.

A serological cohort study modeled how quickly vaccine-acquired antibodies decline and estimated a first half-life of roughly ten years, meaning that about a decade after vaccination, antibody levels have dropped to about half of their peak.⁴ The second halving took longer, around twenty-two years, because the decline slows as levels get lower. This doesn’t mean everyone becomes unprotected after a decade. Protection depends on more than just circulating antibody counts.

Antibodies Are Only Part of the Picture

When doctors check whether someone is “immune” to measles, they typically measure IgG antibodies in the blood. But the immune system’s memory is more layered than a single antibody reading suggests. Even when measurable antibodies dip below traditional protective thresholds, the body often retains memory B cells that can rapidly churn out fresh antibodies if the virus shows up again. It also retains T cells trained to recognize and destroy measles-infected cells.

A study comparing vaccinated people who had lost detectable antibodies to those who still had high antibody levels found that even the seronegative group showed some measles-specific T-cell activity, though at significantly lower levels. The highly seropositive group had about five times as many measles-reactive CD8+ T cells as the seronegative group.⁵ This cellular immune memory helps explain why many people with low or undetectable antibodies still don’t get full-blown measles when exposed. Their T cells kick in as a second line of defense, even when antibodies alone might not be enough to prevent infection entirely.

This is a big part of why the two-dose vaccine schedule works so well in practice despite the gradual decline in antibody levels. The combination of residual antibodies, memory B cells ready to ramp up production, and trained T cells creates multiple layers of protection. For most vaccinated people, this multilayered defense holds for life. But “most” is not “all.”

Primary Versus Secondary Vaccine Failure

When a vaccinated person gets measles, doctors want to know which of two fundamentally different things went wrong. In primary vaccine failure, the person’s immune system never responded to the vaccine in the first place. The vaccine was given, but it didn’t “take,” perhaps because maternal antibodies interfered (common when the first dose is given too early), the vaccine was improperly stored, or the person’s immune system simply didn’t mount a response. In secondary vaccine failure, the vaccine initially worked fine, the person developed immunity, but that immunity faded over time until it could no longer prevent infection.

Distinguishing these two failures matters for public health planning, and researchers use a clever lab technique to tell them apart. They measure the “avidity” of a patient’s IgG antibodies, essentially how tightly those antibodies grip the measles virus. Someone experiencing primary vaccine failure has never had their immune system properly trained on measles, so their body produces low-avidity antibodies during the infection, just as it would for any first-time encounter. Someone with secondary vaccine failure already had their immune system primed years ago, so even though their protection waned, their body quickly produces high-avidity antibodies when reinfected.⁶

During a measles epidemic in São Paulo, Brazil, researchers used this avidity test on 159 confirmed cases. Among the 52 patients who had been vaccinated, about half showed high-avidity antibodies, classifying them as secondary vaccine failures, people whose initial vaccine immunity had waned.⁷ The other half showed low-avidity antibodies, meaning the vaccine had never worked for them at all. This roughly even split suggests both types of failure play significant roles during outbreaks.

What “Modified Measles” Looks Like

When vaccinated people do get measles, the disease often looks different from the classic textbook presentation. Doctors call this “modified measles,” and it can be tricky to recognize. During a sustained outbreak in a highly vaccinated population, researchers found that about 15 percent of vaccinated patients with lab-confirmed measles did not meet the standard clinical case definition, mostly because they had low-grade or absent fever.⁸ Ten vaccinated patients had no detectable measles-specific IgM at all, along with significantly milder illness than other patients. Their residual immunity wasn’t enough to prevent infection, but it was enough to blunt the virus’s impact.

The rash itself can look unusual. During an outbreak among vaccinated healthcare workers, eight out of nine cases developed an atypical pinpoint or vesicular rash rather than the classic blotchy red measles rash.⁹ The rash still followed the typical pattern of starting on the face and spreading down the body, but its texture was distinctly different. Modified measles matters because it creates a diagnostic blind spot: clinicians who are looking for the classic high-fever-plus-blotchy-rash presentation may miss these milder cases, allowing continued transmission.

Crucially, people with modified measles can still spread the virus. A documented outbreak traced to a single index case who had received two doses of measles vaccine showed that this person, whose high-avidity antibodies confirmed secondary vaccine failure, transmitted the virus to nine other people.¹⁰ The index patient even had extremely high neutralizing antibody levels, yet was still infectious. Modified measles is milder for the individual, but from a public health standpoint, it can quietly sustain chains of transmission.

Outbreaks in Highly Vaccinated Populations

One of the more unsettling findings in measles epidemiology is that outbreaks can occur even when vaccination rates appear high. A well-documented outbreak at a high school with 98 percent vaccination coverage found that 70 percent of the cases occurred in students who had been vaccinated at age twelve months or older, the age that should have ensured a good immune response. Vaccine failures among those apparently well-vaccinated students served as the source of infection for nearly half the cases in the outbreak.¹¹

This is precisely why the two-dose schedule was introduced. A single dose of measles vaccine produces immunity in roughly 93 to 95 percent of recipients, which sounds impressive but leaves a meaningful gap when you multiply that failure rate across an entire population. The second dose catches most of the people whose immune systems didn’t respond the first time, pushing overall effectiveness above 97 percent. Recent resurgences in the United States, reaching over 2,000 cases in 2025, have underscored how quickly measles exploits even modest declines in herd immunity driven by vaccine hesitancy and pandemic-related disruptions in routine childhood immunization.¹²

Immune Amnesia and the Hidden Cost of Catching Measles

Here is an irony worth understanding: while measles infection produces excellent immunity against measles itself, it actually damages your immunity to everything else. After infecting a person, the measles virus targets and destroys memory B cells and memory T cells, the very cells your immune system built up over years of encountering other pathogens and receiving other vaccines.¹³ This phenomenon, known as immune amnesia, means that a child who recovers from measles may lose protection they previously had against diseases like influenza, pneumonia, or other infections they had already been vaccinated against or survived.

The research characterizing immune amnesia has been conducted in animal models with ferrets and macaques and corroborated in studies of European populations.¹⁴ The practical consequence is sobering: epidemiological studies have shown that childhood mortality from infections other than measles increases in the months and even years following a measles outbreak. The virus essentially resets portions of the immune system, leaving survivors more vulnerable to a wide range of other threats. This is one of the strongest arguments for measles vaccination beyond just preventing measles itself. The vaccine, because it uses a weakened virus that doesn’t aggressively target immune cells the way wild measles does, provides protection against measles without triggering this immune amnesia.

Infants and the Gap in Protection

Newborns arrive with some measles protection borrowed from their mothers, in the form of antibodies that crossed the placenta during pregnancy. But how long that protection lasts depends heavily on how the mother acquired her immunity. A longitudinal study found that infants of women who had natural measles lost their passive protection at a median of about 3.8 months, while infants of vaccinated women lost theirs at a median of less than one month.¹⁵ The reason is straightforward: naturally immune mothers have higher antibody levels to begin with, so they pass more antibodies to their babies, and it takes longer for those antibodies to decay below protective thresholds.

This creates a practical vulnerability. In most countries, the first dose of measles vaccine is given between nine and fifteen months of age. That leaves a window of several months during which infants have no protection at all, a window that is wider for babies born to vaccinated mothers than for babies born to mothers who had natural measles. As more of the childbearing population consists of women who were vaccinated rather than naturally infected, this gap grows. It is one of the underappreciated consequences of transitioning from a world where everyone caught measles as a child to one where most people are protected by vaccines.

People With Compromised Immune Systems

For immunocompromised individuals, the usual rules about measles immunity don’t apply in the same way. The cellular arm of the immune response, particularly CD8+ T cells, plays a central role in clearing measles virus from the body. In people with compromised cellular immunity, whether from HIV, certain cancers, organ transplants, or immunosuppressive medications, the virus clearance process can fail entirely. Rather than recovering and building lifelong immunity, these patients may develop progressive and often fatal complications like giant cell pneumonia or measles inclusion body encephalitis.¹⁶

These individuals also cannot receive the live measles vaccine safely, since even the weakened vaccine virus could cause disease in someone whose immune system cannot control it. They depend entirely on the herd immunity of the community around them for protection. When vaccination rates drop below the threshold needed to keep measles from circulating, immunocompromised people are among the first and most severely affected.

When Measles Never Fully Leaves the Body

There is one scenario where measles persists not as a second infection but as a continuation of the first. Subacute sclerosing panencephalitis, or SSPE, is a rare and invariably fatal neurological disease that develops years after an initial measles infection, typically seven to ten years later. During the long incubation period, the measles virus establishes a persistent infection in the brain, accumulating mutations that make it increasingly neuropathogenic.¹³ The mutated virus suppresses its own ability to replicate normally, which is part of how it evades detection by the immune system for so long.

SSPE is not a reinfection. The patient’s immune system successfully cleared the acute measles infection years earlier and built strong antibodies against it. But a tiny reservoir of virus, hidden in brain cells where the immune system has limited reach, slowly transforms into something the original immune response was not designed to handle. Children who had measles before their first birthday are at especially high risk, and the condition has become extremely rare in countries with high vaccination rates. It serves as a grim reminder that the consequences of measles infection can extend far beyond the acute illness, and that “lifelong immunity to measles” and “complete viral clearance” are not always the same thing.

How Doctors Confirm Whether It Is Really Measles Again

If you have been vaccinated or previously had measles and develop a rash illness that looks suspicious, lab testing can determine what is actually going on. Standard diagnosis relies on detecting measles-specific IgM antibodies, which appear during an active infection. But as noted earlier, some vaccinated patients with confirmed measles never produce detectable IgM, which means the standard test can miss modified cases.

For cases where doctors need to determine whether a vaccinated patient is experiencing genuine measles and whether it represents a primary or secondary vaccine failure, the IgG avidity assay offers a highly accurate tool. In validation studies, this assay demonstrated sensitivity above 90 percent and specificity above 98 percent in distinguishing between high-avidity antibodies (indicating a previously primed immune system) and low-avidity antibodies (indicating a first-time response).¹⁷ In elimination settings where every case matters for surveillance, this kind of detailed classification helps public health authorities understand whether ongoing transmission is being driven by pockets of unvaccinated people or by waning immunity in vaccinated populations, two problems that require different responses.

For the individual patient, the practical takeaway is simpler. If you had confirmed measles as a child, the odds of getting it again are vanishingly small. If you were vaccinated, your protection is excellent but not absolute, and it may diminish somewhat over the decades. Adults who are unsure of their immunity, particularly healthcare workers, international travelers, or anyone born during the transition years when vaccine schedules were still being standardized, can get a blood test to check their antibody levels and receive a booster dose if needed.